pyrroles has been researched along with Colitis, Granulomatous in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JW; Kim, SY | 1 |
| Heo, JD; Jeong, EJ; Kim, NH; Kim, YN; Lee, S; Lee, SM; Rho, JR | 1 |
| Chu, FF; Doroshow, JH; Esworthy, RS; Gao, Q; Shen, B | 1 |
| Biemans, VBC; Bodelier, AGL; de Boer, NKH; de Vries, AC; Dijkstra, G; Hoekstra, J; Hoentjen, F; Horjus Talabur Horje, CS; Jansen, JM; Löwenberg, M; Oldenburg, B; Pierik, MJ; Römkens, TEH; Sleutjes, JAM; Srivastava, N; van Bodegraven, AA; van der Meulen-de Jong, AE; van der Woude, CJ; van Schaik, FDM; Weersma, RK; West, RL | 1 |
| Alayo, QA; Beniwal-Patel, P; Christophi, GP; Ciorba, MA; Cohen, BL; Colombel, JF; Deepak, P; Dimopoulos, C; Fenster, M; Gutierrez, A; Ha, C; Hirten, RP; Khatiwada, A; Patel, A; Pekow, J; Rubin, DT; Syal, G; Ungaro, RC; Wang, W; Yarur, A | 1 |
| Faubion, WA; Papadakis, KA; Ramos, GP | 1 |
| Boland, BS; Vermeire, S | 1 |
| Lee, SH; Seo, GS | 1 |
| Chan, G; D'Haens, GR; Higgins, PDR; Maller, E; Mele, L; Moscariello, M; Niezychowski, W; Panés, J; Su, C; Wang, W | 1 |
| Cao, C; Dulai, PS; Lasch, K; Osterman, MT; Riaz, F; Sandborn, WJ | 1 |
| Koch, S; Peyrin-Biroulet, L; Vuitton, L | 1 |
| Boers-Sonderen, MJ; Hoentjen, F; Jacobs, JF; Mulder, SF; Nagtegaal, ID; van Herpen, CM; Wanten, GJ | 1 |
| Ghosh, S; Niezychowski, W; Panes, J; Sandborn, WJ; Vranic, I; Wang, W | 1 |
| Danese, S; Olivera, P; Peyrin-Biroulet, L | 1 |
| Chan, G; Colombel, JF; D'Haens, G; Feagan, BG; Healey, P; Higgins, PDR; Maller, E; Marren, A; Moscariello, M; Niezychowski, W; Panaccione, R; Panés, J; Sandborn, WJ; Sands, BE; Schreiber, S; Vermeire, S; Wang, W | 1 |
| Bredberg, A; Grip, O; Janciauskiene, S | 1 |
| Grip, O; Janciauskiene, S | 1 |
| D'Haens, G; Löwenberg, M | 1 |
| Grip, O; Janciauskiene, S; Lindgren, S | 1 |
6 review(s) available for pyrroles and Colitis, Granulomatous
| Article | Year |
|---|---|
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Topics: Adamantane; Colitis; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Piperidines; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
Targeting Specific Immunologic Pathways in Crohn's Disease.
Topics: Antibodies, Monoclonal, Humanized; Cell Adhesion Molecules; Cell Movement; Crohn Disease; Endothelium, Vascular; Gastrointestinal Agents; Humans; Immunologic Factors; Integrins; Interleukin-12; Interleukin-12 Subunit p40; Interleukin-23; Janus Kinase Inhibitors; Janus Kinases; Leukocytes; Natalizumab; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; Th1 Cells; Th17 Cells; Ustekinumab | 2017 |
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Topics: B-Lymphocytes; Colitis, Ulcerative; Crohn Disease; Humans; Indans; Janus Kinase 1; Janus Kinase Inhibitors; Oligonucleotides; Oxadiazoles; Piperidines; Pyridines; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; Smad7 Protein; T-Lymphocytes; Triazoles | 2017 |
[Emerging Therapies: What Are Promising in the Near Future?]
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Crohn Disease; Gastrointestinal Agents; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Ustekinumab | 2018 |
Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inflammatory Bowel Diseases; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; United States; United States Food and Drug Administration | 2013 |
Novel targets for inflammatory bowel disease therapeutics.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Adhesion Molecules; Certolizumab Pegol; Colitis, Ulcerative; Crohn Disease; Humans; Immunoglobulin Fab Fragments; Infliximab; Natalizumab; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Tumor Necrosis Factor-alpha; Ustekinumab | 2013 |
4 trial(s) available for pyrroles and Colitis, Granulomatous
| Article | Year |
|---|---|
Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
Topics: Adult; Crohn Disease; Female; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
Topics: Adult; Animals; Blood Chemical Analysis; C-Reactive Protein; Crohn Disease; Feces; Female; Humans; Janus Kinases; Leukocyte L1 Antigen Complex; Male; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Topics: Adult; C-Reactive Protein; Crohn Disease; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Severity of Illness Index | 2017 |
Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Chemokine CCL8; Crohn Disease; CX3C Chemokine Receptor 1; Female; Follow-Up Studies; Gene Expression Regulation; Heptanoic Acids; Humans; Leukocyte L1 Antigen Complex; Lipopolysaccharide Receptors; Male; Monocytes; Pyrroles; Receptors, CCR2; Receptors, Chemokine; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Tumor Necrosis Factor-alpha; Young Adult | 2008 |
9 other study(ies) available for pyrroles and Colitis, Granulomatous
| Article | Year |
|---|---|
(10
Topics: Animals; Aquatic Organisms; Azepines; Caco-2 Cells; Coculture Techniques; Colitis, Ulcerative; Crohn Disease; Dinoprostone; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Intestines; Porifera; Pyrroles; THP-1 Cells | 2019 |
Dexamethasone and Tofacitinib suppress NADPH oxidase expression and alleviate very-early-onset ileocolitis in mice deficient in GSH peroxidase 1 and 2.
Topics: Animals; Apoptosis; Crohn Disease; Dexamethasone; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Ileum; Inflammation; Inflammatory Bowel Diseases; Mice; Mice, Inbred C57BL; NADPH Oxidase 1; NADPH Oxidases; Oxidation-Reduction; Peroxidases; Piperidines; Pyrimidines; Pyrroles | 2019 |
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Topics: Adult; Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Middle Aged; Netherlands; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Registries; Treatment Outcome; Tumor Necrosis Factor-alpha; Ustekinumab | 2020 |
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.
Topics: Crohn Disease; Humans; Inflammatory Bowel Diseases; Piperidines; Pyrimidines; Pyrroles | 2021 |
Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Biological Products; Colitis, Ulcerative; Crohn Disease; Databases, Factual; Gastrointestinal Agents; Health Services Accessibility; Humans; Infliximab; Insurance Coverage; Insurance, Health; Piperidines; Pyrimidines; Pyrroles; United States; Ustekinumab | 2019 |
Severe exacerbation of Crohn's disease during sunitinib treatment.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Crohn Disease; Disease Progression; Fatal Outcome; Glucocorticoids; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prednisone; Pyrroles; Recurrence; Risk Factors; Severity of Illness Index; Sunitinib; Treatment Outcome | 2014 |
Next generation of small molecules in inflammatory bowel disease.
Topics: Administration, Oral; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Humans; Immunologic Factors; Indans; Inflammatory Bowel Diseases; Oxadiazoles; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.
Topics: Adult; Atorvastatin; C-Reactive Protein; Chemokine CXCL10; Crohn Disease; Cytokines; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Young Adult | 2009 |
Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin.
Topics: Adolescent; Adult; Atorvastatin; Biomarkers; Case-Control Studies; Chemokine CCL2; Crohn Disease; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophage Migration-Inhibitory Factors; Male; Middle Aged; Monocytes; Pyrroles; Tumor Necrosis Factor-alpha | 2004 |